OncoMatch/Clinical Trials/NCT06834282
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Is NCT06834282 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including CER-1236 and Cyclophosphamide for aml.
Treatment: CER-1236 · Cyclophosphamide · Fludarabine · Mesna — This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: permanently integrated, genetically modified cell product
Prior therapy with a permanently integrated, genetically modified cell product
Lab requirements
Blood counts
absolute lymphocyte count >0.3 x 10^9/l prior to apheresis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Davis Comprehensive Cancer Center · Sacramento, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Sarah Cannon Research Insitute · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06834282 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior permanently integrated, genetically modified cell product disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages